The Shorter lab, led by Dr. James Shorter at the University of Pennsylvania, explores mechanisms to counter deleterious phase transitions in neurodegenerative disease. Our multidisciplinary team, including Dr. Christopher Donnelly (University of Pittsburgh) and Dr. Robert Kalb (Northwestern University), is dedicated to uncovering therapeutic modalities to mitigate TDP-43 proteinopathy. Supported by the Kissick Family Foundation, our current project seeks to uncover short RNAs that solubilize the TDP-43 conformers that underpin frontotemporal dementia.